Literature DB >> 21837489

[Renal cell carcinoma: what is new in 2010?].

I Tsaur1, A Haferkamp.   

Abstract

This overview presents new insights into renal cell carcinoma (RCC). The search for new target structures for targeted therapy as well as diagnostic and prognostic markers continues to remain a desirable area of research. Investigations are focusing on the use of well-established and new therapeutic agents for metastatic RCC and an increasingly liberal indication for organ-sparing surgery for renal tumors. The response to systemic treatment in metastatic RCC is also being evaluated in defined subpopulations.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21837489     DOI： 10.1007/s00120-011-2676-6

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  19 in total

1.  A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Authors:  Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Marc Colombel; Laurence Klotz; Eila Skinner; Thomas Keane; Sandrine Marreaud; Sandra Collette; Richard Sylvester
Journal:  Eur Urol       Date:  2010-12-22       Impact factor: 20.096

2.  Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Authors:  Martin E Gore; Clare L Griffin; Barry Hancock; Poulam M Patel; Lynda Pyle; Michael Aitchison; Nicholas James; Roderick T D Oliver; Jozef Mardiak; Tahera Hussain; Richard Sylvester; Mahesh K B Parmar; Patrick Royston; Peter F A Mulders
Journal:  Lancet       Date:  2010-02-10       Impact factor: 79.321

3.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Authors:  Robert J Motzer; Bernard Escudier; Stephane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Andrea Kay; Alain Ravaud
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

5.  Urinary biomarkers for the early diagnosis of kidney cancer.

Authors:  Jeremiah J Morrissey; Amy N London; Jingqin Luo; Evan D Kharasch
Journal:  Mayo Clin Proc       Date:  2010-04-07       Impact factor: 7.616

6.  Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older.

Authors:  Brian R Lane; Robert Abouassaly; Tianming Gao; Christopher J Weight; Adrian V Hernandez; Benjamin T Larson; Jihad H Kaouk; Inderbir S Gill; Steven C Campbell
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

7.  Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy.

Authors:  Christopher J Weight; Casey Lythgoe; Raman Unnikrishnan; Brian R Lane; Steven C Campbell; Amr F Fergany
Journal:  Urology       Date:  2011-03-21       Impact factor: 2.649

8.  Oncologic long-term outcome of elective nephron-sparing surgery versus radical nephrectomy in patients with renal cell carcinoma stage pT1b or greater in a matched-pair cohort.

Authors:  Frederik C Roos; Walburgis Brenner; Melanie Müller; Claudia Schubert; Wolfgang J Jäger; Joachim W Thüroff; Christian Hampel
Journal:  Urology       Date:  2010-12-08       Impact factor: 2.649

9.  Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Authors:  G G Malouf; P Camparo; S Oudard; G Schleiermacher; C Theodore; A Rustine; J Dutcher; B Billemont; O Rixe; E Bompas; A Guillot; L Boccon-Gibod; J Couturier; V Molinié; B Escudier
Journal:  Ann Oncol       Date:  2010-02-12       Impact factor: 32.976

10.  Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.

Authors:  S Yang; P de Souza; E Alemao; J Purvis
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.